指南与共识炎症性肠病

关于炎症性肠病临床试验中糖皮质激素合理管理的国际共识

An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.
指南 / 共识 · Gastroenterology · 2025-05-28

该国际共识通过多阶段改良德尔菲法制定,基于对安慰剂对照试验中糖皮质激素管理规则的系统综述,提出在炎症性肠病药物试验的筛选期、诱导期和维持期管理糖皮质激素的建议,并定义糖皮质激素相关终点,强调通过加速减量和缩短固定剂量期来减少糖皮质激素暴露,并提供无糖皮质激素缓解的标准化定义。

要点

  • 共识建议在筛选期、诱导期和维持期标准化管理糖皮质激素,并定义相关终点。
  • 强调通过加速减量和缩短固定剂量期来减少糖皮质激素暴露。
  • 提供无糖皮质激素缓解的标准化定义以优化试验设计。

核心结论

  • 这些建议将有助于优化试验设计,并促进适当、可接受且标准化的随机对照试验糖皮质激素处理实践。

研究设计与样本

  • 通过系统综述MEDLINE、Embase和Cochrane对照试验中心注册库,确定晚期疗法安慰剂对照试验中使用的糖皮质激素管理规则。
  • 采用改良德尔菲法,经过2轮调查问卷和批准会议,制定国际专家共识建议。

主要发现

  • 建议涉及炎症性肠病药物试验筛选期、诱导期和维持期的糖皮质激素管理,并定义糖皮质激素相关终点。
  • 强调通过加速减量和缩短固定剂量期来减少糖皮质激素暴露,使其更贴近临床实践。
  • 提供无糖皮质激素缓解的标准化定义建议。

关键数值与推荐

  • 建议在筛选期、诱导期和维持期管理糖皮质激素,并定义糖皮质激素相关终点。
  • 强调通过加速减量和缩短固定剂量期来减少糖皮质激素暴露。
  • 提供无糖皮质激素缓解的标准化定义。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Approval of new therapies for inflammatory bowel disease (IBD) requires rigorously designed and well-executed randomized controlled trials (RCTs). Corticosteroids remain a cornerstone of IBD induction therapy, and many patients in trials are enrolled while taking corticosteroids. Despite this, approaches to corticosteroid management in RCTs have been highly heterogeneous, often differing from clinical practice. This negatively impacts patients' willingness to participate due to prolonged corticosteroid exposure and may potentially bias outcomes in the clinical trial. Our aim is to provide comprehensive standardized recommendations on key aspects of corticosteroid use in IBD clinical trials through a multiphase, international expert consensus, with a goal to help inform and standardize practice in future RCTs. METHODS: The consensus was informed by a systematic review of MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials, which determined the corticosteroid management rules used in placebo-controlled trials of advanced therapies in IBD. International expert consensus recommendations for all aspects of corticosteroid management in RCTs were then developed using a modified Delphi process with 2 rounds of survey questions and a ratification meeting. RESULTS: These recommendations propose management of corticosteroids during screening, induction, and maintenance phases of pharmacologic trials in IBD and define corticosteroid-related end points. We emphasize the need for minimizing corticosteroid exposure through expedited tapering and shorter fixed-dosing periods that more closely reflect clinical care and provide recommendations for standardized definitions of corticosteroid-free remission. CONCLUSIONS: These recommendations will serve to optimize trial design and facilitate appropriate, acceptable, and standardized RCT corticosteroid handling practices.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Hanžel J, Solitano V, Vuyyuru SK, et al. An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease. Gastroenterology. 2025. PMID: 40446946. doi:10.1053/j.gastro.2025.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。